Pfizer Deferred Revenue 2011-2026 | PFE

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.

Features of the metric

Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Annual Deferred Revenue Pfizer

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
784 M	1.51 B	2.7 B	2.52 B	3.07 B	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
3.07 B	784 M	2.12 B

Quarterly Deferred Revenue Pfizer

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
924 M	1.12 B	1.01 B	2.02 B	2.53 B	2.5 B	2.2 B	1.29 B	1.75 B	2.52 B	6.19 B	3.8 B	3.11 B	3.07 B	3.53 B	4.29 B	2.05 B	1.11 B	1.11 B	1.11 B	1.11 B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
6.19 B	924 M	2.3 B

Deferred Revenue of other stocks in the Biotechnology industry

Issuer	Deferred Revenue	Price	% 24h	Market Cap	Country
Scholar Rock Holding Corporation SRRK	33.2 M	$ 43.62	-1.33 %	$ 5 B	USA
MorphoSys AG MOR	86.5 M	-	2.43 %	$ 254 M	Germany
Aeterna Zentaris AEZS	2.19 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	283 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	517 K	-	-	$ 1.01 B	USA
AIkido Pharma AIKI	240 K	-	1.93 %	$ 17.4 M	USA
I-Mab IMAB	563 K	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	15.9 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	124 K	-	2.54 %	$ 160 B	France
Midatech Pharma plc MTP	1.3 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.69 M	-	-1.52 %	$ 24.7 M	USA
Arena Pharmaceuticals ARNA	1.11 M	-	-6.81 %	$ 3.04 B	USA
Applied Genetic Technologies Corporation AGTC	6.3 M	-	-	$ 26.5 M	USA
Acorda Therapeutics ACOR	227 K	-	-24.86 %	$ 820 K	USA
bluebird bio BLUE	2.28 M	-	-	$ 546 M	USA
Avid Bioservices CDMO	39.9 M	-	-	$ 789 M	USA
Adverum Biotechnologies ADVM	1.85 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	2.91 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	165 K	-	-9.65 %	$ 45.9 M	USA
Stoke Therapeutics STOK	11.9 M	$ 33.98	0.83 %	$ 2.01 B	USA
EyePoint Pharmaceuticals EYPT	17.8 M	$ 13.09	0.23 %	$ 959 K	USA
BeiGene, Ltd. BGNE	187 M	-	0.49 %	$ 251 B	Cayman-islands
China SXT Pharmaceuticals SXTC	586 K	$ 1.38	4.55 %	$ 1.96 M	China
Takeda Pharmaceutical Company Limited TAK	682 B	$ 18.16	0.55 %	$ 28.4 B	Japan
BioDelivery Sciences International BDSI	1.72 M	-	-4.8 %	$ 255 M	USA
Cara Therapeutics CARA	22.3 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	11 M	-	-	$ 3.74 B	USA
CureVac N.V. CVAC	158 M	-	-	$ 867 M	Germany
Equillium EQ	15.7 M	$ 2.06	-	$ 118 M	USA
Theravance Biopharma TBPH	98 K	$ 14.97	-1.45 %	$ 753 M	Cayman-islands
CRISPR Therapeutics AG CRSP	15.8 M	$ 47.18	-0.79 %	$ 4.24 B	Schweiz
Arbutus Biopharma Corporation ABUS	7.57 M	$ 4.46	0.22 %	$ 855 M	Canada